IBOV 183,827.59 ▲ 0.46% IPSA 11,055.91 ▼ 0.73% IPC MEX 65,071.30 ▲ 0.20% MERVAL 2,782,561 ▼ 0.59% COLCAP 2,558.92 ▼ 0.79% BVL PERÚ 60,220.45 ▲ 0.32% USD/BRL5.20▼ 0.43% USD/MXN18.06▲ 0.10% USD/CLP972.08▲ 0.38% USD/COP3,323▲ 0.62% USD/PEN3.44▼ 0.01% USD/ARS1,524▼ 0.05% USD/UYU40.27▲ 3.67% USD/PYG5,843▲ 2.30% USD/BOB11.96▲ 0.45% USD/DOP59.27▲ 0.12% USD/CRC452.68▲ 2.68% USD/GTQ7.64▲ 3.13% USD/HNL26.87▲ 3.23% USD/NIO36.62▲ 0.34% USD/VES856.92▲ 0.01% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.70▲ 1.64% EUR/BRL5.90▲ 0.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 183,827.59 ▲ 0.46% IPSA 11,055.91 ▼ 0.73% IPC MEX 65,071.30 ▲ 0.20% MERVAL 2,782,561 ▼ 0.59% COLCAP 2,558.92 ▼ 0.79% BVL PERÚ 60,220.45 ▲ 0.32% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Wednesday, September 30, 2026

Hypera’s Founder Unites Shareholders to Block Rival Takeover

By · July 8, 2025 · 2 min read

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Argentina gives Britain two weeks over Falklands oil”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

Brazil’s Hypera, one of the country’s largest drugmakers, now has a new controlling group. Founder João Alves de Queiroz Filho joined with major investors Maiorem and Votorantim to control 53% of the company’s shares.

This move, made official in July 2025, comes after months of pressure from EMS, another big Brazilian pharmaceutical company. Queiroz Filho, who owns 27%, increased his stake after EMS tried to buy a large part of Hypera in late 2024.

EMS offered to buy up to 20% of Hypera’s shares at R$30 each, a 17% premium over the market price. If accepted, the deal would have created a company with R$16 billion in yearly sales and R$5 billion in earnings before taxes and other costs.

Free daily brief — no card needed
Get every Market Reports story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

Hypera’s board rejected the offer, saying it undervalued the company. After the failed bid, EMS bought 6% of Hypera’s shares and used financial contracts to control another 2%.

This showed EMS still wanted influence. In response, Queiroz Filho and his allies formed a united front to keep control of Hypera and avoid a hostile takeover.

Hypera’s Founder Unites Shareholders to Block Rival Takeover
Hypera’s Founder Unites Shareholders to Block Rival Takeover.
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

Votorantim, a large Brazilian group, doubled its Hypera stake to 11%, showing faith in the company’s future. The new agreement between these shareholders still needs approval from Brazil’s competition authority.

Hypera’s defensive move comes after a period of uncertainty. When EMS first made its offer, Hypera’s stock dropped 14% to R$21.95, reflecting investor worries about the company’s future.

Despite the drama, Hypera remains a top player in Brazil’s drug market, known for both over-the-counter and prescription medicines. This battle for control highlights how important ownership is in Brazil’s pharmaceutical industry.

The new control group wants to keep Hypera independent and strong in a market where size and bargaining power matter. The outcome will affect prices, competition, and investment in Brazilian healthcare for years to come.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.